Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOP628 in cKit-positive Tumors and AML
NCT02221505Phase 1Terminated
- Sponsor
- Novartis
- Start
- Dec 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules, Cytotoxic ADCs, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of LOP628 in solid tumor and acute myeloid leukemia (AML) (3 arms), sponsored by Novartis. Primary endpoint: Incident rate of dose limiting toxicities at Month 12. Started Dec 2014; status: terminated.
02
Drugs
LOP628
03
Conditions
solid tumoracute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02221505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221505.